Skip to main content

Advertisement

SpringerLink
Log in

Cancer cachexia: medical management

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Cachexia is a complex metabolic syndrome associated with many chronic or end-stage diseases, especially cancer, and is characterized by loss of muscle with or without loss of fat mass. The management of cachexia is a complex challenge that should address the different causes underlying this clinical event with an integrated or multimodal treatment approach targeting the different factors involved in its pathophysiology.

Materials and methods

The purpose of this article was to review the current medical treatment of cancer-related cachexia, in particular focusing on combination therapy and ongoing research.

Results

Among the treatments proposed in the literature for cancer-related cachexia, some proved to be ineffective, namely, cyproheptadine, hydrazine, metoclopramide, and pentoxifylline. Among effective treatments, progestagens are currently considered the best available treatment option for cancer-related cachexia, and they are the only drugs approved in Europe. Drugs with a strong rationale that have failed or have not shown univocal results in clinical trials so far include eicosapentaenoic acid, cannabinoids, bortezomib, and anti-TNF-alpha MoAb. Several emerging drugs have shown promising results but are still under clinical investigation (thalidomide, selective cox-2 inhibitors, ghrelin mimetics, insulin, oxandrolone, and olanzapine).

Conclusions

To date, despite several years of co-ordinated efforts in basic and clinical research, practice guidelines for the prevention and treatment of cancer-related muscle wasting are lacking, mainly because of the multifactorial pathogenesis of the syndrome. From all the data presented, one can speculate that one single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans WJ, Morley JE, Argiles J et al (2008) Cachexia: a new definition. Clin Nutr 27:793–799

    Article  CAS  PubMed  Google Scholar 

  2. Thomas DR (2007) Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 26:389–399

    Article  PubMed  Google Scholar 

  3. Boddaert MS, Gerritsen WR, Pinedo HM (2006) On our way to targeted therapy for cachexia in cancer? Curr Opin Oncol 18:335–340

    Article  CAS  PubMed  Google Scholar 

  4. Loprinzi CL, Ellison NM, Schaid DJ et al (1990) Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127–1132

    Article  CAS  PubMed  Google Scholar 

  5. Loprinzi CL, Kugler JW, Sloan JA et al (1999) Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17:3299–3306

    CAS  PubMed  Google Scholar 

  6. Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567–573

    Article  CAS  PubMed  Google Scholar 

  7. Mantovani G, Maccio A, Massa E, Madeddu C (2001) Managing cancer-related anorexia/cachexia. Drugs 61:499–514

    Article  CAS  PubMed  Google Scholar 

  8. Mantovani G, Maccio A, Bianchi A et al (1995) Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25:135–141

    Article  CAS  PubMed  Google Scholar 

  9. Mantovani G, Maccio A, Esu S et al (1997) Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33:602–607

    Article  CAS  PubMed  Google Scholar 

  10. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF (1998) Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 82:553–560

    Article  CAS  PubMed  Google Scholar 

  11. Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev CD004310

  12. Femia RA, Goyette RE (2005) The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 19:179–187

    Article  CAS  PubMed  Google Scholar 

  13. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1974) Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607–1609

    Article  CAS  PubMed  Google Scholar 

  14. Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M (1984) Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 288:27

    Article  CAS  Google Scholar 

  15. Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense N−3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479–1486

    Article  CAS  PubMed  Google Scholar 

  16. Jatoi A, Rowland K, Loprinzi CL et al (2004) An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22:2469–2476

    Article  CAS  PubMed  Google Scholar 

  17. Fearon KC, Barber MD, Moses AG et al (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24:3401–3407

    Article  CAS  PubMed  Google Scholar 

  18. Dewey A, Baughan C, Dean T, Higgins B, Johnson I (2007) Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev CD004597

  19. Strasser F, Luftner D, Possinger K et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394–3400

    Article  CAS  PubMed  Google Scholar 

  20. Jatoi A, Alberts SR, Foster N et al (2005) Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer 13:381–386

    Article  PubMed  Google Scholar 

  21. Wiedenmann B, Malfertheiner P, Friess H et al (2008) A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 6:18–25

    CAS  PubMed  Google Scholar 

  22. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54:540–545

    Article  CAS  PubMed  Google Scholar 

  23. Lai V, George J, Richey L et al (2008) Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 30:67–74

    Article  PubMed  Google Scholar 

  24. DeBoer MD (2008) Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 24:806–814

    Article  CAS  PubMed  Google Scholar 

  25. Strasser F, Lutz TA, Maeder MT et al (2008) Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 98:300–308

    Article  CAS  PubMed  Google Scholar 

  26. Neary NM, Small CJ, Wren AM et al (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2832–2836

    Article  CAS  PubMed  Google Scholar 

  27. Garcia J (2007) A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol 25:abstr # 9133

    Google Scholar 

  28. Lundholm K, Korner U, Gunnebo L et al (2007) Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 13:2699–2706

    Article  CAS  PubMed  Google Scholar 

  29. Laviano A, Muscaritoli M, Cascino A et al (2005) Branched-chain amino acids: the best compromise to achieve anabolism? Curr Opin Clin Nutr Metab Care 8:408–414

    Article  CAS  PubMed  Google Scholar 

  30. Eley HL, Russell ST, Tisdale MJ (2007) Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 407:113–120

    Article  CAS  PubMed  Google Scholar 

  31. van Norren K, Kegler D, Argiles JM et al (2009) Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 100:713–722

    Article  PubMed  Google Scholar 

  32. Lesser G, Case D, Ottery F et al (2008) ASCO Meeting. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. Proc Am Soc Clin Onc 26(15S):505s

    Google Scholar 

  33. Braiteh F, Dalal S, Khuwaja A, David H, Bruera E, Kurzrock R (2008) Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer. J Clin Oncol 26: May 20 suppl; abstr # 20529

  34. Argiles JM, Lopez-Soriano FJ, Busquets S (2008) Novel approaches to the treatment of cachexia. Drug Discov Today 13:73–78

    Article  CAS  PubMed  Google Scholar 

  35. Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95

    Article  CAS  PubMed  Google Scholar 

  36. Cerchietti LC, Navigante AH, Castro MA (2007) Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59:14–20

    CAS  PubMed  Google Scholar 

  37. Mantovani G, Madeddu C, Maccio A et al (2004) Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 13:1651–1659

    CAS  PubMed  Google Scholar 

  38. Mantovani G, Maccio A, Madeddu C et al (2006) A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15:1030–1034

    Article  CAS  PubMed  Google Scholar 

  39. Mantovani G, Maccio A, Madeddu C et al (2003) The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 37:213–223

    Article  CAS  PubMed  Google Scholar 

  40. Mantovani G, Maccio A, Madeddu C et al (2003) Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 81:664–673

    Article  CAS  PubMed  Google Scholar 

  41. Mantovani G, Maccio A, Madeddu C et al (2003) Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol 22:17–28

    Article  CAS  PubMed  Google Scholar 

  42. Mantovani G, Madeddu C, Gramignano G et al (2003) Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. J Exp Ther Oncol 3:205–219

    Article  CAS  PubMed  Google Scholar 

  43. Mantovani G, Maccio A, Madeddu C et al (2002) Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncol Rep 9:887–896

    CAS  PubMed  Google Scholar 

  44. Mantovani G, Maccio A, Madeddu C et al (2004) Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity. J Exp Ther Oncol 4:69–78

    CAS  PubMed  Google Scholar 

  45. Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43:89–143

    Article  CAS  PubMed  Google Scholar 

  46. Beller E, Tattersall M, Lumley T et al (1997) Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 8:277–283

    Article  CAS  PubMed  Google Scholar 

  47. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66:1279–1282

    Article  CAS  PubMed  Google Scholar 

  48. Tchekmedyian NS, Hickman M, Siau J et al (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268–1274

    CAS  PubMed  Google Scholar 

  49. Loprinzi CL, Michalak JC, Schaid DJ et al (1993) Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11:762–767

    CAS  PubMed  Google Scholar 

  50. Barber MD, Wigmore SJ, Ross JA, Fearon KCH (1997) Eicosapentaenoic acid attenuates cachexia associated with advanced pancreatic cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids 57:204

    Google Scholar 

  51. Falconer JS, Ross JA, Fearon KC, Hawkins RA, O'Riordain MG, Carter DC (1994) Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 69:826–832

    CAS  PubMed  Google Scholar 

  52. Beck SA, Smith KL, Tisdale MJ (1991) Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51:6089–6093

    CAS  PubMed  Google Scholar 

  53. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80–86

    Article  CAS  PubMed  Google Scholar 

  54. Pettegrew JW, Levine J, McClure RJ (2000) Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5:616–632

    Article  CAS  PubMed  Google Scholar 

  55. Mantovani G, Maccio A, Madeddu C et al (2008) Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 24:305–313

    CAS  PubMed  Google Scholar 

  56. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9:4653–4665

    CAS  PubMed  Google Scholar 

  57. Figueras M, Busquets S, Carbo N et al (2004) Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 569:201–206

    Article  CAS  PubMed  Google Scholar 

  58. Harcourt LJ, Holmes AG, Gregorevic P et al (2005) Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 166:1131–1141

    CAS  PubMed  Google Scholar 

  59. Fuster G, Busquets S, Ametller E et al (2007) Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res 67:6512–6519

    Article  CAS  PubMed  Google Scholar 

  60. Evans W, Smith M, Morley J et al. (2007) Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients. J Clin Oncol 25:abstr # 9119

    Google Scholar 

  61. Acharyya S, Guttridge DC (2007) Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 13:1356–1361

    Article  CAS  PubMed  Google Scholar 

  62. Deboer MD, Marks DL (2006) Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 17:199–204

    Article  CAS  PubMed  Google Scholar 

  63. Tan BH, Deans DA, Skipworth RJ, Ross JA, Fearon KC (2008) Biomarkers for cancer cachexia: is there also a genetic component to cachexia? Support Care Cancer 16:229–234

    Article  CAS  PubMed  Google Scholar 

  64. Fearon KC (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44:1124–1132

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Cagliari, Cagliari, Italy

    Giovanni Mantovani & Clelia Madeddu

Authors
  1. Giovanni Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clelia Madeddu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Mantovani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mantovani, G., Madeddu, C. Cancer cachexia: medical management. Support Care Cancer 18, 1–9 (2010). https://doi.org/10.1007/s00520-009-0722-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0722-3

Keywords

Search

Navigation